NASDAQ:SBBP Strongbridge Biopharma (SBBP) Stock Price, News & Analysis → The Military's $700M 'AI Software Bullet' (From Behind the Markets) (Ad) Free SBBP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.95▼$2.0650-Day Range$1.89▼$2.2952-Week Range$1.85▼$4.26Volume684,684 shsAverage Volume866,464 shsMarket Capitalization$135.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Strongbridge Biopharma alerts: Email Address Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About Strongbridge Biopharma Stock (NASDAQ:SBBP)Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.Read More Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> SBBP Stock News HeadlinesFebruary 10, 2024 | investing.comMatinas BioPharma Holdings Inc (MTNB)November 15, 2023 | lse.co.ukLytix Biopharma As Share Price (LYTIX.OL)June 18, 2024 | Prosper Trading Academy (Ad)Beta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)November 4, 2023 | morningstar.comAmbrx Biopharma Inc AMAMAugust 19, 2023 | seekingalpha.comHILS Hillstream BioPharma, Inc.July 1, 2023 | finance.yahoo.comABUS - Arbutus Biopharma CorporationApril 25, 2023 | thestreet.comThe Nominees for Best Biopharma CEO of 2015 Are...January 11, 2023 | marketwatch.comDay One Biopharma Shares Rise 13% After Positive Topline Results for TovorafenibJune 18, 2024 | Prosper Trading Academy (Ad)Beta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)September 22, 2022 | markets.businessinsider.comAccord BioPharma Partners with StoryMD to Deliver Advanced Prostate Cancer Educational Content to Clinicians and PatientsSeptember 23, 2021 | apnews.comStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by ...September 23, 2021 | finance.yahoo.comStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.September 14, 2021 | stockhouse.comXeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge BiopharmaSeptember 9, 2021 | apnews.comStrongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris ...August 31, 2021 | apnews.comLeading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders ...August 31, 2021 | finance.yahoo.comSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With XerisAugust 5, 2021 | sfgate.comStrongbridge Biopharma: Q2 Earnings SnapshotAugust 5, 2021 | finance.yahoo.comStrongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateAugust 2, 2021 | finance.yahoo.comStrongbridge Biopharma plc Announces Commencement of Mailing of Proxy StatementJuly 29, 2021 | finance.yahoo.comStrongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021July 29, 2021 | finance.yahoo.comStrongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in IssueJuly 28, 2021 | nasdaq.comStrongbridge Biopharma's (NASDAQ:SBBP) Stock Price Has Reduced 48% In The Past Three YearsJuly 27, 2021 | finance.yahoo.comStrongbridge Biopharma (SBBP) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseJuly 27, 2021 | apnews.comStrongbridge Biopharma plc Announces Dates of Special Shareholder Meetings in Connection with ...July 26, 2021 | msn.comBRIEF-Strongbridge Biopharma Plc, Unit, Avenue Venture Opportunities Fund Enter Amendment To A Term Loan AgreementSee More Headlines Receive SBBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Strongbridge Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2021Today6/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SBBP CUSIPN/A CIK1634432 Webwww.strongbridgebio.com Phone(610) 254-9200FaxN/AEmployees72Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,080,000.00 Net Margins-115.67% Pretax MarginN/A Return on Equity-66.82% Return on Assets-36.21% Debt Debt-to-Equity Ratio0.38 Current Ratio3.00 Quick Ratio2.95 Sales & Book Value Annual Sales$30.73 million Price / Sales4.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book2.04Miscellaneous Outstanding Shares67,829,000Free FloatN/AMarket Cap$135.66 million OptionableOptionable Beta1.58 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesJohn H. JohnsonChief Executive Officer & DirectorRichard S. KollenderPresident & Chief Financial OfficerFredric CohenChief Medical OfficerBrian ConnerChief Compliance OfficerPeter J. ValentinssonSenior Vice President-Global Technical OperationsKey CompetitorsAssembly BiosciencesNASDAQ:ASMBORIC PharmaceuticalsNASDAQ:ORICTravere TherapeuticsNASDAQ:TVTXCorbus PharmaceuticalsNASDAQ:CRBPY-mAbs TherapeuticsNASDAQ:YMABView All Competitors SBBP Stock Analysis - Frequently Asked Questions How were Strongbridge Biopharma's earnings last quarter? Strongbridge Biopharma plc (NASDAQ:SBBP) announced its earnings results on Thursday, August, 5th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.09. The biotechnology company had revenue of $10.04 million for the quarter, compared to analysts' expectations of $8.83 million. Strongbridge Biopharma had a negative net margin of 115.67% and a negative trailing twelve-month return on equity of 66.82%. What other stocks do shareholders of Strongbridge Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Energy Transfer (ET), Selecta Biosciences (SELB), Rigel Pharmaceuticals (RIGL), Agile Therapeutics (AGRX), Dicerna Pharmaceuticals (DRNA), Dynavax Technologies (DVAX) and Matinas BioPharma (MTNB). This page (NASDAQ:SBBP) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Strongbridge Biopharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Strongbridge Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.